SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SYNTHETECH - NZYM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (343)11/17/2000 11:38:16 AM
From: Dan Gibbs  Read Replies (2) of 372
 
There is an interesting front page article in today's WSJ about Cor Therapeutic's Integrilin and how it is winning out over ReoPro to prevent clots during coronary angioplasty. There are three approved drugs in this class of glycoprotein IIb/IIIa inhibitors of platelet aggregation. ReoPro is a fragment of a monoclonal antibody, Aggrastat (Merck) is a non-peptide, and Intergrilin is a synthetic cyclic heptapeptide containing at least one non-natural amino acid. It is exactly the sort of drug that would need NZYM's "peptide building blocks." If NZYM is not supplying these to Cor, one of its competitors must be.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News